Peking Union Medical College Hospital: Carcinoma, Non-Small-Cell Lung trials

The registry lists 23 Carcinoma, Non-Small-Cell Lung studies with Peking Union Medical College Hospital as lead sponsor. 12 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 14Phase 3 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLCRecruitingNCT07452003Not applicable
• The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)RecruitingNCT06861543Phase 1
• Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNot yet recruitingNCT06752408Phase 2
• Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical MutationsRecruitingNCT06674343Phase 3
• ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICIRecruitingNCT06388031Phase 2
• A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingNCT06142617Phase 2
• Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05751018Phase 2
• Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)RecruitingNCT05559645Not applicable
• A Real World Study of Ensartinib in Advanced ALK-positive NSCLCRecruitingNCT05498064
• Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung CancerRecruitingNCT05445310Phase 2
• Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung CancerNot yet recruitingNCT05306847Phase 2
• Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)RecruitingNCT03334864
• Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)Active, not recruitingNCT05599789Phase 2
• Neoadjuvant/Adjuvant Pembrolizumab Plus ChemotherapyActive, not recruitingNCT05383716Phase 2
• A Real-world Study of Durvalumab for Lung Cancer in ChinaStatus unknownNCT04672759
• Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics ModelsStatus unknownNCT04646837Phase 1/2
• SinTilimab After Radiation (STAR Study)CompletedNCT04167657Phase 2
• Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerStatus unknownNCT04164745Phase 2
• A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal MetastasisStatus unknownNCT02803619
• Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLCStatus unknownNCT01755923Phase 2
• Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer PatientsStatus unknownNCT01749072Phase 2
• Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs TherapyStatus unknownNCT01746277Phase 2
• A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue SamplesStatus unknownNCT01382992